Search results for "Pharmacotherapy"

showing 10 items of 283 documents

ITPA deficiency and ribavirin level are still predictive of anaemia in HCV–HIV-coinfected patients receiving ribavirin combined with a first-generati…

2017

Background We aimed to determine the impact of inosine triphosphatase (ITPA) deficiency on ribavirin (RBV)-induced anaemia in HIV–HCV-coinfected patients receiving a triple therapy including the haematotoxic direct-acting antiviral agent boceprevir (BOC). Methods Patients of the ANRS HC27 BocepreVIH study were genotyped for two ITPA single nucleotide polymorphisms involved in ITPA deficiency. RBV trough concentration (Ctrough) was determined at week (W)4 and W8. Impact of ITPA deficiency on anaemia, RBV Ctrough, response and haematotoxicity (grade 3/4 anaemia, erythropoietin [EPO] use, RBV dose reduction or transfusion between day [D]0 and W8) was evaluated. Impact of RBV Ctrough on anaemia…

Malemedicine.medical_specialtyGenotype[SDV]Life Sciences [q-bio]Human immunodeficiency virus (HIV)HIV Infectionsmedicine.disease_causeAntiviral AgentsGastroenterologychemistry.chemical_compoundPharmacotherapyGene FrequencyRisk FactorsInternal medicineRibavirinmedicineHumansGenetic Predisposition to DiseasePharmacology (medical)PyrophosphatasesAllelesComputingMilieux_MISCELLANEOUSPharmacologyCoinfectionbusiness.industryRibavirinAnemiaHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseFirst generation3. Good health[SDV] Life Sciences [q-bio]Infectious DiseaseschemistryMutationCoinfectionDrug Therapy CombinationFemaleITPAbusinessMetabolism Inborn ErrorsINOSINE TRIPHOSPHATASE
researchProduct

Leucocyte Interferon-alpha for Patients with Chronic Hepatitis C Intolerant to Other alpha-Interferons

2003

Background: Alpha-interferon (α-IFN) is the treatment of choice for chronic hepatitis C but most patients experience adverse effects which sometimes lead to the suspension of therapy. Recently, higher doses of α-IFN or prolonged therapy have increased the number of cases of intolerance. Study Design: In this open study we evaluated the efficacy and safety of leucocyte interferon-alpha (IFNα) [6MU three times a week] in 43 patients with chronic hepatitis C who had been intolerant to previous treatment courses with recombinant or lymphoblastoid IFNα. All patients were treated for 6 months and followed-up for an additional 6 months. End of treatment responders were patients in whom hepatitis C…

Malemedicine.medical_specialtyHepatitis C virusAlpha interferonmedicine.disease_causeAntiviral AgentsInjections IntramuscularGastroenterologyPharmacotherapyInternal medicineLeukocytesHumansImmunology and AllergyMedicinePharmacology (medical)Adverse effectPharmacologybiologybusiness.industryInterferon-alphaGeneral MedicineHepatitis C ChronicMiddle AgedMolecular medicineAnti-thyroid autoantibodiesDiscontinuationPharmacology Toxicology and Pharmaceutics (all)Immunologybiology.proteinFemaleAntibodybusinessBiotechnologyBioDrugs
researchProduct

Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy

2009

Treatment with peginterferon alfa and ribavirin produces a sustained virologic response (SVR) in approximately 60% of hepatitis C virus (HCV)-infected patients. Alternate options are needed for patients who relapse or do not respond to therapy.This prospective, international, multicenter, open-label study evaluated efficacy and safety of peginterferon alfa-2b (1.5 microg/kg/wk) plus weight-based ribavirin (800-1400 mg/day) in 2333 chronic HCV-infected patients with significant fibrosis/cirrhosis whose previous interferon alfa/ribavirin therapy failed. Patients with undetectable HCV-RNA at treatment week (TW) 12 received 48 weeks of therapy; patients with detectable HCV-RNA at TW12 could ent…

Malemedicine.medical_specialtyHepatitis C virusPeginterferon-alfaHepacivirusInterferon alpha-2medicine.disease_causeAntiviral AgentsGastroenterologyPolyethylene Glycolschemistry.chemical_compoundPharmacotherapyInternal medicineRibavirinmedicineHCV ANTIVIRAL THERAPYHumansTreatment FailureInterferon alfaHepatologybusiness.industryRibavirinGastroenterologyInterferon-alphavirus diseasesHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant Proteinsdigestive system diseaseschemistryImmunologyRNA ViralPeginterferon alfa-2bDrug Therapy CombinationFemalebusinessViral loadmedicine.drug
researchProduct

Impact of Pharmacists’ Participation in a Pharmacotherapy Follow-Up Program

2012

Objective. To evaluate the impact of a continuing pharmacy education (CPE) course on Spanish community pharmacists’ participation in a pharmacotherapy follow-up program. Design. Participation in a CPE course offered 4 times over a 4-year period via satellite teleconferencing was monitored and the data analyzed to determine the course’s impact on community pharmacists’ participation in a pharmacotherapy follow-up program. Assessment. Community pharmacists’ participation in the pharmaceutical care CPE course had a slightly positive impact on their participation in the pharmacotherapy follow-up program. In the best profiles, there was a probability of 7.3% that participants would participate i…

Malemedicine.medical_specialtyInstructional Design and Assessmenthealth care facilities manpower and servicesDistance educationeducationPharmacyPharmacistsEducationPharmacotherapyNursinghealth services administrationMedicineHumansGeneral Pharmacology Toxicology and PharmaceuticsEducation Pharmacy ContinuingCurriculumhealth care economics and organizationsPharmaciesbusiness.industryPharmacy educationGeneral Medicinebiochemical phenomena metabolism and nutritionClinical pharmacyPharmaceutical careLogistic ModelsSpainFamily medicinePharmaceutical ServicesFemaleCurriculumbusiness
researchProduct

Clinical Inertia in Poorly Controlled Elderly Hypertensive Patients: A Cross-Sectional Study in Spanish Physicians to Ascertain Reasons for Not Inten…

2013

Clinical inertia, the failure of physicians to initiate or intensify therapy when indicated, is a major problem in the management of hypertension and may be more prevalent in elderly patients. Overcoming clinical inertia requires understanding its causes and evaluating certain factors, particularly those related to physicians.The objective of our study was to determine the rate of clinical inertia and the physician-reported reasons for it.An observational, cross-sectional, multi-center study was carried out in a primary care setting. We included 512 physicians, with a consecutive sampling of 1,499 hypertensive patients with clinical inertia.Clinical inertia was defined when physicians did n…

Malemedicine.medical_specialtyPediatricsMedicinaCross-sectional studyTreatment outcomeAlternative medicineMEDLINEPharmacotherapyPhysiciansmedicineHumansCorPharmacology (medical)Hypertension diagnosisIntensive care medicineAntihypertensive AgentsAgedPhysician-Patient Relationsbusiness.industryGeneral MedicineMiddle AgedCross-Sectional StudiesTreatment OutcomeMulticenter studySpainHypertensionFemaleClinical CompetenceClinical competenceCardiology and Cardiovascular MedicinebusinessAmerican Journal of Cardiovascular Drugs
researchProduct

Rats with congenital hydronephrosis show increased susceptibility to renal ischemia‐reperfusion injury

2020

Abstract Many drug candidates have shown significant renoprotective effects in preclinical models; however, there is no clinically used effective pharmacotherapy for acute kidney injury. The failure to translate from bench to bedside could be due to misleading results from experimental animals with undetected congenital kidney defects. This study was performed to assess the effects of congenital hydronephrosis on the functional capacity of tubular renal transporters as well as kidney sensitivity to ischemia‐reperfusion (I‐R)‐induced injury in male Wistar rats. Ultrasonography was used to distinguish healthy control rats from rats with hydronephrosis. L‐carnitine or furosemide was administer…

Malemedicine.medical_specialtyPhysiologyhydronephrosis pharmacokinetics renal ischemia-reperfusion ultrasonographyUrologyUrine030204 cardiovascular system & hematologyKidneylcsh:Physiology03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePharmacotherapyhydronephrosisPharmacokineticsFurosemideCarnitinePhysiology (medical)medicineAnimalsRats WistarDiureticsHydronephrosisCreatinineKidneylcsh:QP1-981business.industryAcute kidney injuryFurosemideOriginal ArticlesultrasonographyAcute Kidney Injurymedicine.diseaseRatsrenal ischemia‐reperfusionmedicine.anatomical_structurechemistryReperfusion InjuryOriginal ArticleDisease SusceptibilitybusinessCell Adhesion Moleculespharmacokinetics030217 neurology & neurosurgerymedicine.drugPhysiological Reports
researchProduct

Uric acid, phosphate and oxalate stones: treatment and prophylaxis.

2004

Medical treatment for the most commonly encountered types of renal stones is described. Nowadays treatment for uric acid stones is well-defined: alkalinizing urine is easy with drugs that are sufficiently active and well enough managed. Relapse is avoided in a high percentage of patients. Medical treatment of phosphate or calcium stones is a more open question as results are far from satisfactory compared with intra- and extra-corporeal approaches which are often minimally invasive and well accepted by both patient and urologist. Relapses are not easy to control because prophylactic measures such as changes in lifestyle and diet are never activated or because they are adopted for a brief pe…

Malemedicine.medical_specialtyUrologymedicine.medical_treatmentCalcium oxalateUrineLithotripsyRisk AssessmentOxalatechemistry.chemical_compoundKidney CalculiPharmacotherapyLithotripsymedicineHumansCalcium Oxalatebusiness.industryPhosphatePrognosisSurgeryUric AcidchemistryUric acidDrug Therapy CombinationFemalebusinessMedical therapyUrologia internationalis
researchProduct

Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10

2009

SummaryUnanticipated elevation of the INR is common in patients receiving warfarin. We performed a prospective cohort study of 107 warfarintreated patients with INR values of more than 10 who received a single 2.5 mg dose of oral vitamin K. During the first week, one patient experienced major bleeding, and one died. In the first 90 days after enrolment four patients had major bleeding (3.7%, 1.0% to 9.3%), eight patients (7.5%, 3.3% to 14.2%) died and two had objectively confirmed thromboembolism. Based on our low rate of observed major bleeding we conclude that 2.5 mg of oral vitamin K is a reasonable treatment for patients with INR values of more than 10 who are not actively bleeding.

Malemedicine.medical_specialtyVitamin Kmedicine.drug_classAdministration OralHemorrhagePharmacotherapyInternal medicinemedicineCoagulopathyHumansInternational Normalized RatioProspective StudiesProspective cohort studyAgedAged 80 and overVenous ThrombosisVascular diseasebusiness.industryAnticoagulantWarfarinAnticoagulantsHematologyMiddle Agedmedicine.diseaseThrombosisSurgeryFemaleINR oral anticoagulantsWarfarinbusinessFollow-Up Studiesmedicine.drugCohort studyThrombosis and Haemostasis
researchProduct

Insights from Experiences on Antiplatelet Drugs in Stroke Prevention: A Review

2020

Reduction of hazard risk of cerebral ischemic event (stroke, transient ischemic attack (TIA)) represents the hard point to be achieved from primary or secondary preventive strategy in the best clinical practice. However, results from clinical trials, recommendations, guidelines, systematic review, expert opinions, and meta-analysis debated on the optimal pharmacotherapy to achieve the objective. Aspirin and a number of antiplatelet agents, alone or in combination, have been considered from large trials focused on stroke prevention. The present review summarizes, discusses results from trials, and focuses on the benefits or disadvantages originating from antiplatelet drugs. Sections of the r…

Malemedicine.medical_specialtyaspirinHealth Toxicology and Mutagenesisdipyridamolelcsh:MedicineStroke.Review030204 cardiovascular system & hematology03 medical and health sciencesTherapeutic approach0302 clinical medicinePharmacotherapyDouble-Blind MethodpreventionSecondary PreventionmedicineHumanscardiovascular diseasesIntensive care medicineStrokeAgedclopidogrelAspirinPreventive strategybusiness.industrylcsh:RPublic Health Environmental and Occupational HealthMiddle AgedClopidogrelmedicine.diseasestrokecombined drug therapyClinical trialDiabetes Mellitus Type 2Ischemic Attack TransientStroke preventionDrug Therapy CombinationFemalebusinesscilostazolPlatelet Aggregation Inhibitors030217 neurology & neurosurgerymedicine.drugInternational Journal of Environmental Research and Public Health
researchProduct

A Patient Registry to Improve Patient Safety: Recording General Neurosurgery Complications

2016

Background To improve the transparency of the local health care system, treatment cost was recently referenced to disease related groups. Treatment quality must be legally documented in a patient registry, in particular for the highly specialized treatments provided by neurosurgery departments. Methods In 2013 we have installed a patient registry focused on cranial neurosurgery. Surgeries are characterized by indication, treatment, location and other specific neurosurgical parameters. Preoperative state and postoperative outcome are recorded prospectively using neurological and sociological scales. Complications are graded by their severity in a therapy-oriented complication score system (C…

Medical DoctorsHealth Care Providerslcsh:MedicineNervous System Procedures0302 clinical medicineHealth careInterventional RadiologyMedicine and Health SciencesMedicineGrading (education)lcsh:ScienceMultidisciplinaryPatient registryRadiology and ImagingHospitalsProfessionsData Acquisition030220 oncology & carcinogenesisNeurosurgeryResearch Articlemedicine.medical_specialtyComputer and Information SciencesNeurosurgerySurgical and Invasive Medical Procedures610 Medicine & health1100 General Agricultural and Biological Sciences03 medical and health sciencesPatient safety10180 Clinic for NeurosurgeryPharmacotherapy1300 General Biochemistry Genetics and Molecular BiologyPhysiciansEndoscopic SurgerySurgical RadiologySurgeons1000 Multidisciplinarybusiness.industrylcsh:REndoscopyInternal qualitySurgeryHealth CareHealth Care FacilitiesEmergency medicinePeople and PlacesPopulation Groupingslcsh:QComplicationbusiness030217 neurology & neurosurgery
researchProduct